Clark Eliana
SEC CIK 1914448 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NTLA | Intellia Therapeutics, Inc. | EVP, Chief Technical Off | 93.9K | — | $690.4K | 17 | 2022-03-01 | 2026-03-02 |
Most active insiders at NTLA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | LEONARD JOHN M | Pres, CEO, Dir | — | $1.44M |
| 2 | Cohen Fred E | Dir | $1.40M | — |
| 3 | Dulac Edward J III | EVP, CFO | — | $234.2K |
| 4 | BASTA JAMES | EVP, GC | — | $112.4K |
| 5 | Lebwohl David | EVP, Chief Medical Off | — | $109.6K |
| 6 | Dube Michael P | VP, CAO | — | $104.4K |
| 7 | Clark Eliana | EVP, Chief Technical Off | — | $96.0K |
| 8 | Schultes Birgit C | EVP, CSO | — | $78.9K |
| 9 | Bhanji Muna | Dir | — | — |
| 10 | Keresty Georgia | Dir | — | — |
Transactions 17
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-03 | 2026-03-01 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | EVP, Chief Technical Off | A - Grant | $0.00 | +7,353 | 94.5K | +8% | $0 |
| D | 2026-03-03 | 2026-03-02 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | EVP, Chief Technical Off | S - Sale | $13.78 | -607 | 93.9K | -0.6% | -$8,364 |
| 2026-01-07 | 2026-01-05 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | EVP, Chief Technical Off | S - Sale | $9.21 | -9,515 | 87.1K | -10% | -$87.6K | |
| 2025-07-03 | 2025-07-01 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | EVP, Chief Technical Off | S - Sale | $9.82 | -1,022 | 95.4K | -1% | -$10.0K | |
| D | 2025-03-04 | 2025-03-04 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | EVP, Chief Technical Off | S - Sale | $8.99 | -679 | 95.4K | -0.7% | -$6,104 |
| D | 2025-03-04 | 2025-03-01 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | EVP, Chief Technical Off | A - Grant | $0.00 | +32.0K | 96.0K | +50% | $0 |
| M | 2025-01-06 | 2025-01-02+ | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | EVP, Chief Technical Off | S - Sale | $12.17 | -7,978 | 64.0K | -11% | -$97.1K |
| 2024-07-03 | 2024-07-01 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | EVP, Chief Technical Off | S - Sale | $22.93 | -405 | 71.5K | -0.6% | -$9,287 | |
| D | 2024-03-05 | 2024-03-04 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | EVP, Chief Technical Off | S - Sale | $32.99 | -605 | 71.5K | -0.8% | -$20.0K |
| D | 2024-03-05 | 2024-03-01 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | EVP, Chief Technical Off | A - Grant | $0.00 | +31.2K | 72.1K | +76% | $0 |
| M | 2024-01-05 | 2024-01-03 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | EVP, Chief Technical Off | S - Sale | $29.50 | -4,608 | 40.8K | -10% | -$136.0K |
| 2023-07-06 | 2023-07-03 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | EVP, Chief Technical Off | S - Sale | $40.51 | -360 | 45.1K | -0.8% | -$14.6K | |
| D | 2023-06-22 | 2023-06-20 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | EVP, Chief Technical Off | M - OptEx | $12.27 | +5,000 | 50.1K | +11% | +$61.4K |
| D | 2023-06-22 | 2023-06-20 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | EVP, Chief Technical Off | S - Sale+OE | $45.00 | -5,000 | 45.1K | -10% | -$225.0K |
| DM | 2023-03-03 | 2023-03-01 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | EVP, Chief Technical Off | A - Grant | $0.00 | +30.7K | 39.0K | +368% | $0 |
| M | 2023-01-06 | 2022-07-01+ | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | EVP, Chief Technical Off | S - Sale | $37.65 | -2,028 | 16.2K | -11% | -$76.4K |
| D | 2022-03-07 | 2022-03-01 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | EVP, Chief Technical Off | A - Grant | $0.00 | +10.5K | 16.2K | +187% | $0 |
Purchase Sale Sale after option exercise All abbreviations